U.S. Serial No. 14/859,042
`
`Attorney Docket No. 46682-701501
`
`AMENDMENTS TO THE CLAIMS
`
`This listing of claims replaces all prior versions and listing of claims in the above-
`
`referenced patent application.
`
`Listing of Claims
`
`1.
`
`(Currently Amended) An ophthalmic composition, comprising from about 0.001 wt% to about
`
`0.05 wt% of a deuterated muscarinic antagonist: wherein the deuterated muscarinic antagonist is
`
`deuterated atropine or deuterated atropine sulfate.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`(Cancelled).
`
`(Cancelled).
`
`(Original) The ophthalmic composition of claim 1, wherein the deuterated muscarinic antagonist
`
`is a compound having the structure:
`
`wherein at least one of Ha, Hb, He, Hd, and He is substituted with deuterium.
`
`(Original) The compound of claim 4, wherein H61 is substituted with deuterium.
`
`(Original) The compound of claim 4, wherein Hb is substituted with deuterium.
`
`(Original) The compound of claim 4, wherein Hc is substituted with deuterium.
`
`(Original) The compound of claim 4, wherein HCl is substituted with deuterium.
`
`(Original) The compound of claim 4, wherein He is substituted with deuterium.
`
`

`

`U.S. Serial No. 14/859,042
`
`Attorney Docket No. 46682-701501
`
`10.
`
`(Original) The compound of claim 4, wherein at least two of Ha, Hb, He, Hd, and H‘3 are
`
`substituted with deuterium.
`
`11.
`
`(Original) The compound of claim 10, wherein H61 and Hb are substituted with deuterium.
`
`12.
`
`(Original) The compound of claim 10, wherein H61 and H‘3 are substituted with deuterium.
`
`13.
`
`(Original) The compound of claim 10, wherein Hb and H‘3 are substituted with deuterium.
`
`14.
`
`(Original) The compound of claim 10, wherein Hc and H‘3 are substituted with deuterium.
`
`15.
`
`(Original) The compound of claim 10, wherein Hc and HCl are substituted with deuterium.
`
`16.
`
`(Original) The compound of claim 4, wherein at least three of Ha, Hb, Hc, Hd, and H‘3 are
`
`substituted with deuterium.
`
`17.
`
`(Original) The compound of claim 16, wherein Ha, Hb, and H‘3 are substituted with deuterium.
`
`18.
`
`(Original) The compound of claim 16, wherein Ha, He, and HCl are substituted with deuterium.
`
`19.
`
`(Original) The compound of claim 16, wherein Hb, He, and HCl are substituted with deuterium.
`
`20.
`
`(Original) The compound of claim 16, wherein He, Hd, and H‘3 are substituted with deuterium.
`
`21.
`
`(Original) The compound of claim 4, wherein Ha, Hb, Hc, Hd, and H‘3 are substituted with
`
`deuterium.
`
`22.
`
`(Original) The ophthalmic composition of claim 1, wherein the ophthalmic composition is
`
`fiirther formulated as an aqueous solution with water.
`
`23.
`
`(Original) The ophthalmic composition of claim 22, wherein the ophthalmic composition
`
`formulated with water has a pH of one of: less than about 7.5, less than about 7.3, less than about
`
`7.2, less than about 7. 1, less than about 7, less than about 6.8, less than about 6.5, less than about
`
`6.4, less than about 6.3, less than about 6.2, less than about 6. 1, less than about 6, less than about
`
`

`

`U.S. Serial No. 14/859,042
`
`Attorney Docket No. 46682-701501
`
`5.9, less than about 5.8, less than about 5.2, less than about 4.8, less than about 4.2, or less than
`
`about 4 after extended period of time under storage condition.
`
`(Original) The ophthalmic composition of claim 22, wherein the ophthalmic composition
`
`comprises one of: less than 5% of D20, less than 4% of D20, less than 3% of D20, less than 2%
`
`of D20, less than 1% of D20, less than 0.5% of D20, less than 0.1% of D20, or 0% of D20.
`
`(Original) The ophthalmic composition of claim 1, wherein the ophthalmic composition
`
`comprises one of: at least about 80%, at least about 85%, at least about 90%, at least about 93%,
`
`at least about 95%, at least about 97%, at least about 98%, or at least about 99% of the muscarinic
`
`antagonist based on initial concentration after extended period of time under storage condition.
`
`(Original) The ophthalmic composition of claim 1, wherein the ophthalmic composition further
`
`has a potency of one of: at least 80%, at least 85%, at least 90%, at least 93%, at least 95%, at
`
`least 97%, at least 98%, or at least 99% after extended period of time under storage condition.
`
`(Original) The ophthalmic composition of claim 1, wherein the storage condition has a storage
`
`temperature of from about 2°C to about 10°C or from about 16°C to about 26°C.
`
`(Original) The ophthalmic composition of claim 1, wherein the deuterated muscarinic antagonist
`
`is present in the composition at a concentration of one of: from about 0.001 wt% to about 0.04
`
`wt%, from about 0.001 wt% to about 0.03 wt%, from about 0.001 wt% to about 0.025 wt%, from
`
`about 0.001 wt% to about 0.02 wt%, from about 0.001 wt% to about 0.01 wt%, from about 0.001
`
`wt% to about 0.008 wt%, or from about 0.001 wt% to about 0.005 wt%.
`
`(Original) The ophthalmic composition of claim 1, wherein the ophthalmic composition further
`
`comprises an osmolarity adjusting agent, a preservative, a buffer agent, a tonicity adjusting agent,
`
`or a combination thereof.
`
`(Original) The ophthalmic composition of claim 1, wherein the ophthalmic composition has a
`
`dose-to-dose muscarinic antagonist concentration variation of one of: less than 50%, less than
`
`40%, less than 30%, less than 20%, less than 10%, or less than 5%.
`
`24.
`
`25.
`
`26.
`
`27.
`
`28.
`
`29.
`
`30.
`
`

`

`U.S. Serial No. 14/859,042
`
`Attorney Docket No. 46682-701501
`
`31.
`
`32.
`
`33.
`
`34.
`
`35.
`
`36.
`
`37.
`
`38.
`
`39.
`
`(Original) The ophthalmic composition of claim 1, wherein the ophthalmic composition is
`
`essentially free of procaine and benactyzine, or pharmaceutically acceptable salts thereof.
`
`(Original) The ophthalmic composition of claim 1, wherein the ophthalmic composition is
`
`fiirther formulated as an aqueous solution with deuterated water.
`
`(Original) The ophthalmic composition of claim 32, wherein the ophthalmic composition
`
`formulated with deuterated water has a pD of one of: less than about 8, less than about 7.5, less
`
`than about 7.3, less than about 7.2, less than about 7.1, less than about 7, less than about 6.8, less
`
`than about 6.5, less than about 6.4, less than about 6.3, less than about 6.2, less than about 6.1,
`
`less than about 6, less than about 5.9, less than about 5.8, less than about 5.2, less than about 4.8,
`
`or less than about 4.5 after extended period of time under storage condition.
`
`(Original) The ophthalmic composition of claim 32, wherein the ophthalmic composition
`
`comprises one of: less than 5% of H20, less than 4% oszO, less than 3% of H20, less than 2%
`
`oszO, less than 1% oszO, less than 0.5% oszO, less than 0.1% of H20, or 0% of H20.
`
`(Original) The ophthalmic composition of claim 32, wherein the ophthalmic composition further
`
`comprises a pD adjusting agent.
`
`(Currently Amended) The ophthalmic composition of claim 35, wherein the pD adjusting
`
`agent comprises 961 deuterated hydrochloric acid, NaOD deuterated sodium hydroxide,
`
`919399919 deuterated acetic acid, or @6989; deuterated citric acid.
`
`(Original) The ophthalmic composition of claim 1, wherein the ophthalmic composition is not
`
`formulated as an injectable formulation.
`
`(Original) The ophthalmic composition of claim 1, wherein the ophthalmic composition is
`
`formulated as an ophthalmic solution for the treatment of an ophthalmic disorder.
`
`(Original) The ophthalmic composition of claim 38, wherein the ophthalmic disorder or
`
`condition is pre-myopia, myopia, or progression of myopia.
`
`

`

`U.S. Serial No. 14/859,042
`
`Attorney Docket No. 46682-701501
`
`40.
`
`41.
`
`42.
`
`43.
`
`44.
`
`45.
`
`46.
`
`47.
`
`48.
`
`49.
`
`50.
`
`(Withdrawn) A method of arresting myopia development or preventing myopia development,
`
`comprising administering to an eye of an individual in need thereof an effective amount of an
`
`ophthalmic composition of claim 1.
`
`(Withdrawn) The method of claim 40, wherein the ophthalmic composition is stored at between
`
`about 2 0C to about 10 0C prior to first use.
`
`(Withdrawn) The method of claim 40, wherein the ophthalmic composition is stored at between
`
`about 16 0C to about 26 0C after first use.
`
`(Withdrawn) A compound having the structure:
`
`wherein at least one of Ha, Hb, He, Hd, and He is substituted with deuterium.
`
`(Withdrawn) The compound of claim 43, wherein H61 is substituted with deuterium.
`
`(Withdrawn) The compound of claim 43, wherein Hb is substituted with deuterium.
`
`(Withdrawn) The compound of claim 43, wherein Hc is substituted with deuterium.
`
`(Withdrawn) The compound of claim 43, wherein HCl is substituted with deuterium.
`
`(Withdrawn) The compound of claim 43, wherein He is substituted with deuterium.
`
`(Withdrawn) The compound of claim 43, wherein at least two of Ha, Hb, He, Hd, and H‘3 are
`
`substituted with deuterium.
`
`(Withdrawn) The compound of claim 49, wherein H61 and Hb are substituted with deuterium.
`
`

`

`U.S. Serial No. 14/859,042
`
`Attorney Docket No. 46682-701501
`
`51.
`
`(Withdrawn) The compound of claim 49, wherein H61 and H‘3 are substituted with deuterium.
`
`52.
`
`(Withdrawn) The compound of claim 49, wherein Hb and H‘3 are substituted with deuterium.
`
`53.
`
`(Withdrawn) The compound of claim 49, wherein Hc and H‘3 are substituted with deuterium.
`
`54.
`
`(Withdrawn) The compound of claim 49, wherein Hc and HCl are substituted with deuterium.
`
`55.
`
`(Withdrawn) The compound of claim 43, wherein at least three of Ha, Hb, He, Hd, and H‘3 are
`
`substituted with deuterium.
`
`56.
`
`(Withdrawn) The compound of claim 55, wherein Ha, Hb, and H‘3 are substituted with deuterium.
`
`57.
`
`(Withdrawn) The compound of claim 55, wherein Ha, He, and HCl are substituted with deuterium.
`
`58.
`
`(Withdrawn) The compound of claim 55, wherein Hb, He, and HCl are substituted with deuterium.
`
`59.
`
`(Withdrawn) The compound of claim 55, wherein He, Hd, and H‘3 are substituted with deuterium.
`
`60.
`
`(Withdrawn) The compound of claim 43, wherein Ha, Hb, HG, Hd, and H‘3 are substituted with
`
`deuterium.
`
`61.
`
`(Withdrawn) A compound having the structure:
`
`D D
`DscxN DD D
`D
`D
`D
`D
`
`D
`
`D
`
`0
`
`0
`
`D
`
`D
`D
`
`D
`FD
`OD
`
`